Evidence map›Paper›PMID 26930291›Full record

ArticlePloS one2016

Progress in Reversing the HIV Epidemic through Intensified Access to Antiretroviral Therapy: Results from a Nationally Representative Population-Based Survey in Kenya, 2012.

Andrea A Kim, Irene Mukui, Lucy N'gan'ga, Abraham Katana, Dan Koros, Joyce Wamicwe, Kevin M De Cock, KAIS Study Group

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrea A KimUS Centers for Disease Control and Prevention, Division of Global HIV and Tuberculosis, Nairobi, Kenya.
Irene MukuiMinistry of Health, National AIDS and STI Control Programme, Nairobi, Kenya.
Lucy N'gan'gaUS Centers for Disease Control and Prevention, Division of Global HIV and Tuberculosis, Nairobi, Kenya.
Abraham KatanaUS Centers for Disease Control and Prevention, Division of Global HIV and Tuberculosis, Nairobi, Kenya.
Dan KorosUS Centers for Disease Control and Prevention, Division of Global HIV and Tuberculosis, Nairobi, Kenya.
Joyce WamicweMinistry of Health, National AIDS and STI Control Programme, Nairobi, Kenya.
Kevin M De CockUS Centers for Disease Control and Prevention, Division of Global HIV and Tuberculosis, Nairobi, Kenya.
KAIS Study Group

Funding

CGH CDC HHS U19 GH000069PEPFAR GH000069PEPFAR PS001805PEPFAR PS001814
6 · The paper itself

Abstract

backgroundIn 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) called for 90% of persons living with HIV (PLHIV) to know their status, 90% of these to be on antiretroviral therapy (ART), and 90% of these to be virally suppressed by 2020 (90-90-90). It is not clear whether planned ART scale-up in countries whose eligibility criteria for ART initiation are based on recommendations from the 2013 World Health Organization treatment guidelines will be sufficient to meet UNAIDS' new global targets. MATERIALS AND

methodsUsing data from a nationally representative population-based household survey of persons in Kenya we compared coverage and unmet need associated with HIV diagnosis, ART, and viral suppression among PLHIV aged 15-64 years in 2012 based on criteria outlined in the 2014 national ART guidelines and UNAIDS' 90-90-90 goals. Estimates were weighted to account for sampling probability and nonresponse.

resultsEight in ten PLHIV aged 15-64 years needed ART based on treatment eligibility. Need for treatment based on the national treatment policy was 97.4% of treatment need based on UNAIDS' 90-90-90 goals, requiring an excess of 24,000 PLHIV to access treatment beyond those eligible for ART to achieve UNAIDS' 90-90-90 treatment target. The gap in treatment coverage was high, ranging from 43.1% nationally to 52.3% in Nyanza among treatment-eligible PLHIV and 44.6% nationally to 52.4% in Nyanza among all PLHIV.

conclusionMaintaining the current pace of ART scale-up in Kenya will result in thousands of PLHIV unreached, many with high viral load and at-risk of transmitting infection to others. Careful strategies for reaching 90-90-90 will be instrumental in determining whether intensified access to treatment can be achieved to reach all who require ART.

Indexed as

AdolescentAdultAnti-HIV AgentsEpidemicsFemaleHealth Care SurveysHealth Services AccessibilityHIV InfectionsHumansKenyaMaleMiddle AgedPrevalenceYoung AdultAnti-HIV Agents

Identifiers

PMID26930291
PMCPMC4773218

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.